The first experience of application infliximab at patients about a steroid-refractory and a steroid-dependent forms of a nonspecific ulcerative colitis

Abstract


It is well known that corticosteroids are the current first-line therapy for patients with moderate or severe form ulcerative colitis (UC). About 30-35% of patients do not respond to corticosteroids and require alternative anti-inflammatory agent. The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in mucosal inflammation. Infliximab, a monoclonal antibody against TNF-alpha has been proved highly effective in the treatment of steroid–dependent and steroid–resistant forms of UC.

Белгородская областная клиническая больница Святителя Иоасафа, Белгородский государственный университет

Author for correspondence.
Email: okb@bel.ru
доктор медицинских наук, профессор, заведующий кафедрой клинических дисциплин ИПМО Белгородского государственного университета, главный врач Белго- родской областной клинической больницы Святителя Иоасафа.

Белгородская областная клиническая больница Святителя Иоасафа, Белгородский государственный университет

Email: okb@bel.ru
доктор медицинских наук, профессор кафедры клинических дисциплин ИПМО Белгородского государственного университета.

Белгородская областная клиническая больница Святителя Иоасафа, Белгородский государственный университет

Email: ellochka1981@yandex.ru
врач-хирург отделения гравитационной хирургии Белгородской областной клинической больницы Святителя Иоасафа.

  1. Belousova E.A. Terapiia vospalitel'nykh zabolevanii
  2. kishechnika: nastoiashchee i budushchee.[Therapy of inflammatory diseases bowel: Present and Future.] Vrach 2002; 2: 36-39.
  3. Belousova E.A. Immunnye mekhanizmy pri vospalitel'nykh zabolevaniiakh kishechnika i printsipy selektivnoi immunokorrektsii.[Immune mechanisms in inflammatory bowel disease and immune selective principles.] Ros. zhurn. gastroenterologii, gepatologii, koloproktologii 1999; 9: 4: 48-57.
  4. Belousova E.A., Morozova N.A., Nikitina N.V. Infliksimab (remikeid) v lechenii refrakternykh form bolezni Krona. [Infliximab (Remicade) in the treatment of refractory forms of Crohn's disease.] RMZh 2005; 7: 1: 28-32.
  5. Grigor'eva G.A., Meshalkina N.Iu. Bolezn' Krona.[Crohn's disease.] M.:
  6. OAO «Izdatel'stvo «Meditsina» 2007; 184.
  7. Komarov F.I., Osadchuk A.M., Osadchuk M.A., Kvetnoi
  8. I.M. Nespetsificheskii iazvennyi kolit. [Nonspecific ulcerative colitis] M.: OOO «Meditsinskoe informatsionnoe agentstvo» 2008; 256.
  9. Lopatkina T.N., Moiseev S.V. Ingibitory faktora
  10. nekroza opukholi al'fa v lechenii vospalitel'nykh za-
  11. bolevanii kishechnika.[Inhibitors of tumor necrosis factor-alpha in the treatment of inflammatory bowel disease.] Klinicheskaia farmakologiia i
  12. terapiia 2007; 2-7.
  13. Rumiantsev V.G., Rogozina V.A., Tsaregorodtseva T.M. Infliksimab: novaia era v terapii vospalitel'nykh zabolevanii kishechnika.[Infliximab: a new era in the treatment of inflammatory bowel disease.] Gastroenterologiia 2004; 1: 25-6.
  14. Khalif I.L., Loranskaia I.D. Vospalitel'nye zabolevaniia kishechnika (nespetsificheskii iazvennyi kolit i bolezn' Krona): klinika, diagnostika i lechenie.[Inflammatory bowel disease (ulcerative colitis
  15. and Crohn's disease): clinical features, diagnosis and treatment.] M.:
  16. «Miklosh» 2004; 88.
  17. Shifrin O.S. Remikeid – novyi etap v lechenii vospa-
  18. litel'nykh zabolevanii kishechnika.[Remicade - a new stage in the treatment of inflammatory bowel diseases.] Consilium medicum
  19. ; prilozhenie «Gastroenterologiia» 1: 13-15.
  20. Chey W.Y., Hussain A., Ryan C. et al. Infliksimab dlia
  21. tugoplavkii nespetsificheskogo iazvennogo kolita. [Infliximab for
  22. refractory ulcerative colitis.[ Am J Gastroenterol 2001; 96:
  23. -66.
  24. Feagan B.G. Infliksimab v lechenii bolezni Krona. [Infliximab in the treatment of Crohn’s disease.] Scand J Gastroenterol 2000;14 (Suppl. C). 6B.
  25. Kirsner J.B.Vospalitel'noe zabolevanie kishechnika. [Inflammatory bowel disease] 2000; 800.
  26. Jarnerot G., Hertervig E., Friis-Liby I. et al.
  27. Infliksimab, kak spasitel'naya terapiia pri tiazheloi forme do umerennoi ostryi iazvennyi Kolit: a randomizirovannoe, platsebo-kontroliruemoe issledovanie. [Infliximab as Rescue Therapy in Severe to Moderate Severe Ulcerative Colitis: a Randomised, Placebo-controlled Study.]
  28. Gastroenterology 2005; 128: 1805-11.
  29. Lemann M., Mary J.Y., Duclos B. et al. Infliksimab plius azatioprin dlia patsientov s bolezn'iu steroidozavisimoi Krona: randomizirovannoe platsebo-kontroliruemoe issledovanie.[Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial.] Gastroenterology
  30. ; 130: 4: 1054-61.
  31. Rutgeerts P., Feagan B., Olson A. et al. Randomizirovannoe Platsebo-kontroliruemoe issledovanie infliksimaba terapii dlia Aktivnyi Iazvennyi kolit: AST-1 Trial. [A Randomized
  32. Placebo-Controlled Trial of Infliximab Therapy for Active
  33. Ulcerative Colitis: AST-1 Trial.] Gastroenterology 2005;
  34. (Suppl. 2).
  35. Rutgeerts P., Sanborn W., Feagan B. et al. Infliksimab dlia induktsii i podderzhivaiushchei terapii iazvennogo kolita. [Infliximab for
  36. Induction and Maintenanse Therapy for Ulcerative Colitis.]
  37. N Eng J Med 2005; 353: 2462-76.
  38. Sandborn W., Rachmilewitz D., Hanauer S. et al. Infliksimab Induktsionnye i Maintenanse terapiia iazvennogo kolita: AST-2 Trial. [Infliximab Induction and Maintenanse Therapy for Ulcerative Colitis:
  39. the AST-2 Trial.] Gastroenterology 2005; 128(Suppl. 2).
  40. Sandborn W.J., Targan S.R.Biologicheskaia terapiia vospalitel'nykh
  41. zabolevaniy kishechnika. [Biologic therapy of inflammatory
  42. bowel disease.] Gastroenterology 2002; 122: 6: 1592-607.
  43. Sands B.E., Tremaine W.J., Sanborn W.J. et al.[Infliksimab v lechenii tiazheloi steroid-tugoplavkogo iazvennyi kolita: pilot stu-du.[Infliximab in the treatment of severe steroid-refractory ulcerative colitis:a pilot stu-dy.] IBD 2001; 7: 83-88.

Views

Abstract - 52

PDF (Russian) - 33

PlumX

Dimensions


Copyright (c) 2009 ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies